🚨 May Issue Alert! 🚨 The latest edition of Ophthalmology Times Europe is out now. Stay ahead with the latest research and insights in the field of ophthalmology. Access the May 2024 issue here: https://bit.ly/4dMLSUO
Ophthalmology Times Europe’s Post
More Relevant Posts
-
Our recent Publication joint to PAAO. The COVID-19 pandemic affected medical practice worldwide due to interventions to prevent spreading. Its effect on ophthalmology practices in Latin America has not yet been explored. We aimed to assess the perceptions about the pandemic from countries’ ophthalmological national and subspecialty retina societies affiliated to the Pan-American Association of Ophthalmology (PAAO). #PAAO #ophthalmology https://lnkd.in/dcR7q5XY
To view or add a comment, sign in
-
-
AAO Assessment Finds 10-2 VF Not Useful in Routine Testing ⚠️ In a new Ophthalmic Technology Assessment by the American Academy of Ophthalmology, researchers evaluated the current published literature on the utility of the 10-2 visual field testing strategy for the evaluation and management of early glaucoma, defined here as mean deviation (MD) better than -6 decibels. They concluded that 10-2 VF testing may not be the most useful routine test for patients with early glaucoma, but would provide sufficient additional information for patients with a repeatable defect on the pupillary distance (PD) plot among the central 12 points on the 24-2 or 24-2C VF test. Read more: https://lnkd.in/dpp9xMGT #eyesurgeon #eyesurgery #eyedoctor #eyedoc #ophthalmologist #ophthalmology #vision #visualfield #glaucoma #AAOphth #AAOph
To view or add a comment, sign in
-
-
Most viewed in the last 7 days from JAMA Ophthalmology: What is the association between melatonin use and the development and progression of AMD? https://ja.ma/3z2UKpC
To view or add a comment, sign in
-
-
#Publicationalert Glad to share our recent publication in the British Journal of Ophthalmology! We have shared interesting results on the adjuvant role of topical cyclosporine 1% in acute Stevens-Johnson syndrome. Check out the latest insights in ophthalmology research! #Ophthalmology #ResearchPublication PS- Feels good to be back in research!
To view or add a comment, sign in
-
-
Early Glaucoma Discrimination Index https://lnkd.in/dWedr3DN الحمد لله my 2023 global ophthalmology summit e-poster now on https://lnkd.in/dWdYwB8i
To view or add a comment, sign in
-
Did you know - Just in the last 5 years, #Fortrea had supported the development of 114 Ophthalmology studies globally? Interested to learn more? Drop me a message and I'll connect you with our experts! #ophthalmology #medicaldevices #ophthalmologyclinicaltrials #medicaldevicedevelopment
Fortrea: A clinical ophthalmology leader | Fortrea posted on the topic | LinkedIn
share.postbeyond.com
To view or add a comment, sign in
-
Atropine? Lenses? Axial Length ? Blue Light Control ?
The European Ophthalmology Association, in cooperation with the International Myopia Institute, has open-sourced the Myopia management algorithm paper published in the European Journal of Ophthalmology. The purpose of the Algorithm Annexe is to give practical advice to eye care providers in choosing and developing an effective myopia management strategy for their patients. For free access to the paper, visit the link at: https://lnkd.in/g3vq-U2u #imi #myopia #myopiamanagement
To view or add a comment, sign in
-
-
C.S. Lewis is credited with saying, “You are never too old to set another goal or to dream a new dream.” The sentiment is particularly fitting for the field of ophthalmology today. Learn more about the future of ophthalmology in our newest issue "Visionaries in Practice" at crstoday.com
To view or add a comment, sign in
-
-
�� Dive into the world of Ophthalmology with Dr. Ramanjit Sihota! Check out the fundamentals Questions in Glaucoma videos. Gain insights, enhance your knowledge, and stay ahead in eye health! Watch now and explore the depths of Ophthalmology. https://lnkd.in/eyVVW34X
To view or add a comment, sign in
-
-
We are proud to have our data accepted and published in the American Journal of Ophthalmology, in a paper titled: “Two-Year Performance and Safety Results of the MINIject® Supraciliary Implant in Patients with Primary Open-Angle Glaucoma: Meta-Analysis of the STAR-I, II, III Trials.” The data demonstrates that MINIject® is a safe and effective, bleb-free treatment option for patients with primary open-angle glaucoma requiring low target intraocular pressure for up to 2 years. Find out more in the paper here: https://lnkd.in/eWpg9hh2 #Publication #MINIject #Ophthalmology #MIGS
To view or add a comment, sign in
-